PBYI Puma Biotechnology Inc.

PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. – PBYI

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Puma Biotechnology, Inc. (NYSE: PBYI).

On September 30, 2016, a United States District Judge for the Central District of California United States District Court denied a motion to dismiss in a shareholder class action against Puma, CEO, President, and Chairman Alan H. Auerbach, and Senior Vice President, Finance and Administration and Treasurer Charles R. Eyler. The class action alleged that, in violation of the federal securities laws, Puma and the other defendants failed to inform shareholders that the shift in what its breast cancer drug, called neratinib, could actually treat would require additional studies and push the timeline for filing the NDA into the first quarter of 2016, and that Puma made false and misleading statements concerning the results for its phase 3 trial.

In denying Puma’s motion to dismiss the securities fraud class action, the court stated that the plaintiff had “adequately and specifically alleged why each of these statements and several others could be false or at least misleading.” The court further held that the complaint contained allegations adequate to show that Auerback “knew about the allegedly real trial results when he made the alleged misrepresentations.”

KSF’s investigation is focusing on whether Puma’s officers and/or directors breached their fiduciary duties to Puma’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Puma shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]).

About Kahn Swick & Foti, LLC

KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
29/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Puma Biotechnology Inc.

Puma Biotechnology Inc: 1 director

A director at Puma Biotechnology Inc sold 27,000 shares at 3.367USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule...

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-t...

 PRESS RELEASE

Puma Biotechnology to Present at Barclays Annual Global Healthcare Con...

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live webcast of the presentation will be available on the Puma Biotechnology website at . The presentation will be archived on the website and available for replay for 30 days. About Puma Biotechnology Puma Biotechnology, In...

 PRESS RELEASE

Puma Biotechnology to Present at Barclays Annual Global Healthcare Con...

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live webcast of the presentation will be available on the Puma Biotechnology website at . The presentation will be archived on the website and available for replay for 30 days. About Puma Biotechnology Puma Biotechnology, In...

 PRESS RELEASE

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial...

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch